What is Leerink Partnrs’ Estimate for STOK Q1 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Stoke Therapeutics in a report released on Tuesday, March 18th. Leerink Partnrs analyst M. Goodman forecasts that the company will earn ($0.49) per share for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.79) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at $0.55 EPS.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million.

A number of other brokerages have also weighed in on STOK. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 18th. Chardan Capital restated a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Price Performance

Shares of STOK opened at $8.15 on Friday. The firm has a market cap of $431.68 million, a P/E ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 1 year low of $6.29 and a 1 year high of $17.58. The company has a 50 day simple moving average of $9.47 and a two-hundred day simple moving average of $11.42.

Insider Activity

In other news, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. This trade represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of STOK. Intech Investment Management LLC bought a new stake in Stoke Therapeutics during the 3rd quarter valued at $160,000. Charles Schwab Investment Management Inc. increased its stake in shares of Stoke Therapeutics by 9.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company’s stock valued at $3,885,000 after buying an additional 26,870 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Stoke Therapeutics by 1,589.7% during the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after buying an additional 71,647 shares during the period. Checkpoint Capital L.P. bought a new stake in shares of Stoke Therapeutics in the third quarter valued at about $1,936,000. Finally, RTW Investments LP lifted its stake in Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after acquiring an additional 427,447 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.